

Tanya St. Arnauld (featured on the cover) suffered severe burns on her face and body as a result of a violent assault with acid in Canada in 2012. These severe injuries over large areas of her body formed large scars and caused Tanya substantial pain and limited her range of motion and ability to perform even simple daily tasks.

After 4 treatments with the Lumenis® UltraPulse® by Dr. Jill S. Waibel (Miami Dermatology & Laser Institute), Tanya had already achieved considerable improvement in range of motion and pain, as well as in the appearance of her scars, enabling her to resume her normal life routine. Tanya is now actively engaged in increasing awareness for UltraPulse® laser treatments among other burn survivors.



The SCAAR FX™ treatment, combined with DeepFX™ and ActiveFX™, is the ultimate solution for minimally-invasive scar revision:

		DeepFX™	SCAAR FX™
POWERFUL	Energy	2.5 – 50 mJ	60 – 150 mJ
	Single Pulse Depth	Up to 1500 µm	Up to 4000 µm
VERSATILE	Beam Diameter	120 µm	
	Density	5 – 25 %	1 – 10 %
	Pulse Duration	Up to 265 µsec	Up to 1000 µsec
FAST	Scan Size	22x2 – 10x10 mm	5x5 – 10x10 mm
	Repetition Rate	Up to 600 Hz	Up to 250 Hz
CONVENIENT	Scan Shape	■ ▲ ○	■ ▲ ⬡
	Repeat Mode Delay	0.3 – 1.5 sec	

Warnings and risks

CO₂ lasers are intended solely for use by physicians trained in the use of the Carbon Dioxide laser (10.6 µm) wavelength. Incorrect treatment settings or misuse of the technology can present risk of serious injury to patient and operating personnel. Risks that may be associated with any CO₂ laser procedure may include change of pigmentation, infection, erythema, skin induration or scarring. Read and understand the CO₂ systems and accessories operator manuals for a complete list of intended use, contraindications and risks. The use of Lumenis® CO₂ laser is contraindicated where a patient has taken Accutane (Isotretinoin) within the past 6-12 months, has a history of keloid formation and demonstrate excessive or unusually prolonged erythema.

© 2017 All Rights Reserved. The Lumenis Group of Companies. Lumenis, its logo, UltraPulse, AcuPulse, ActiveFX, DeepFX, TotalFX and SCAAR FX are trademarks or registered trademarks of the Lumenis Group of Companies. Specifications are subject to change without notice. Lumenis is ISO 13485:2003 certified. UltraPulse is CE approved. | UltraPulse is FDA cleared. PB-1007924 Rev B.



 Lumenis Ltd.
Yokneam Industrial Park
6 Hakidma Street P.O.B. 240
Yokneam 2069204, Israel
Tel: +972-4-959-9000

 Lumenis (Germany) GmbH
Heinrich-Hertz-Str 3 D-63303
Dreieich-Dreieichenhain
GERMANY
Tel: +49 (0) 6103 8335 0

EMEA
Dreieich Dreieichenhain,
Germany
T +49 6103 8335 0
F +49 6103 8335 300

Roma, Italy
T +39 06 90 75 230
F +39 06 90 75 269
Hertfordshire, UK
T +44 20 8736 4110
F +44 20 8736 4119

JAPAN
Tokyo, Japan
T +81 3 6743 8300
F +81 3 6743 8301

AMERICAS
San Jose, CA, USA
T +1 408 764 3000
+1 877 586 3647
F +1 408 764 3999

ASIA PACIFIC
Beijing, China
T +86 10 5737 6677
F +86 10 5737 6767
Gurgaon, India
T +91 124 422 07 95
Kowloon, Hong Kong
T +852 217 428 00
F +852 272 251 51

 0473 Rx only

UltraPulse[®] with SCAAR FX[™]

Restoring Hope
to Scar Patients



Changing Patients' Lives with Outstanding Clinical Outcomes

"With UltraPulse's SCAAR FX, I am able to treat deep skin conditions, like hypertrophic scars, with the results of enhanced skin condition and improved quality of life for patients. SCAAR FX has the unique combination of short pulse durations and high energy which enables deep, precise and effective treatment."

Dr. Matteo Tretti Clementoni, Plastic Surgeon



Before

Courtesy of Jill S. Waibel, MD



After



Before

Courtesy of Tan Jun, MD



After



Before

Courtesy of Matteo Tretti Clementoni, MD



3 weeks after 1st treatment



Before

Courtesy of Tan Jun, MD




After

A New Standard of Care

Recent consensus paper by leading panel of physicians (see under 'Selected publications') establishes the following criteria for a safe and effective laser scar treatment:

- 1** Ablative Fractional lasers more effective than PDL, Q-switched and non-ablative lasers. CO₂ preferred over Er:YAG
- 2** Appropriate degree of thermal coagulation to facilitate the remodeling process.
- 3** Treat up to 4mm deep
- 4** Low & Variable Density (1-25%)
- 5** Smallest Spot Size (120um)
- 6** Shortest Pulse Width

The Lumenis® UltraPulse® perfectly meets all criteria.



150mJ, 3% density

Not indicative of clinical results

Selected publications:

Anderson RR, Donelan MB, Hivnor C, Greeson E, Ross EV, Shumaker PR, Uebelhoer NS, Waibel JS. 2014 Feb. Laser treatment of traumatic scars with emphasis on ablative fractional laser resurfacing consensus report. JAMA Dermatol. 150(2):187-193.

Ozog DM, Liu A, Chaffins ML, Ormsby AH, Fincher EF, Chipps LK, Mi QS, Grossman PH, Pui JC, Moy RL. 2013 Jan. Evaluation of clinical results, histological architecture, and collagen expression following treatment of mature burn scars with a fractional carbon dioxide laser. JAMA Dermatol. 149(1):50-57

Qu L, Liu A, Zhou L, He C, Grossman PH, Moy RL, Mi QS, Ozog D. 2012 Sep. Clinical and molecular effects on mature burn scars after treatment with a fractional CO(2) laser. Lasers Surg Med. ;44(7):517-524.

Shumaker PR, Kwan JM, Landers JT, Uebelhoer NS. 2012 Aug. Functional improvements in traumatic scars and scar contractures using an ablative fractional laser protocol. J Trauma Acute Care Surg. 73(2 Suppl 1):S116-121.

Uebelhoer NS, Ross EV, Shumaker PR. 2012 Jun. Ablative fractional resurfacing for the treatment of traumatic scars and contractures. Semin Cutan Med Surg. 31(2):110-120.